Head-To-Head Comparison: Nuvation Bio (NYSE:NUVB) versus Lyell Immunopharma (NASDAQ:LYEL)

Lyell Immunopharma (NASDAQ:LYEL) and Nuvation Bio (NYSE:NUVB) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, institutional ownership, valuation, profitability, analyst recommendations, earnings and risk.

Earnings and Valuation

This table compares Lyell Immunopharma and Nuvation Bio”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lyell Immunopharma	$40,000.00	5,243.00	-$274.45 million	($12.83)	-0.67
Nuvation Bio	$62.90 million	27.10	-$204.63 million	($0.44)	-11.03

Nuvation Bio has higher revenue and earnings than Lyell Immunopharma. Nuvation Bio is trading at a lower price-to-earnings ratio than Lyell Immunopharma, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Lyell Immunopharma and Nuvation Bio’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Lyell Immunopharma	-920,285.25%	-91.62%	-70.50%
Nuvation Bio	-88.18%	-46.59%	-22.01%

Risk & Volatility

Lyell Immunopharma has a beta of -0.03, meaning that its stock price is 103% less volatile than the S&P 500. Comparatively, Nuvation Bio has a beta of 1.61, meaning that its stock price is 61% more volatile than the S&P 500.

Analyst Ratings

This is a summary of recent ratings and recommmendations for Lyell Immunopharma and Nuvation Bio, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lyell Immunopharma	1	1	6	1	2.78
Nuvation Bio	1	2	9	0	2.67

Lyell Immunopharma currently has a consensus target price of $40.86, suggesting a potential upside of 377.30%. Nuvation Bio has a consensus target price of $13.22, suggesting a potential upside of 172.34%. Given Lyell Immunopharma’s stronger consensus rating and higher probable upside, research analysts plainly believe Lyell Immunopharma is more favorable than Nuvation Bio.

Institutional and Insider Ownership

66.0% of Lyell Immunopharma shares are owned by institutional investors. Comparatively, 61.7% of Nuvation Bio shares are owned by institutional investors. 6.2% of Lyell Immunopharma shares are owned by insiders. Comparatively, 30.1% of Nuvation Bio shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

Nuvation Bio beats Lyell Immunopharma on 9 of the 15 factors compared between the two stocks.

About Lyell Immunopharma

Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic. It is also developing LYL797, a genetically and epigenetically reprogrammed ROR1 chimeric antigen receptor (CAR) T cell product candidate that is in Phase 1 clinical trial for the treatment of various solid tumors; and LYL845, a novel epigenetically reprogrammed tumor-infiltrating lymphocytes product candidate, which is in Phase 1 clinical trial targeting multiple solid tumor indications. In addition, the company's preclinical product candidates include LYL119, a ROR1 CAR T-cell product for the treatment of enhanced cytotoxicity; and second generation TIL product. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.

About Nuvation Bio

Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-868, a BD2 selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation, including oncogenes comprising c-myc; NUV-1156, an AR binder Xtandi that address advanced stage prostate cancers with the potential to move into earlier lines typically treated with surgical prostatectomy; and drug-drug conjugate (DDC) platform which leverages a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies to deliver anti-cancer therapeutics to cancer cells, as well as NUV-1176, a PARP inhibitor to address ER+ breast and ovarian cancer. The company was founded in 2018 and is headquartered in New York, New York.